Heron Therapeutics | HRTX - Gross Profit On Sales


Heron Therapeutics reported $23.35M in Gross Profit on Sales for its fiscal quarter ending in September of 2024.





Gross Profit On Sales Change Date
ALKERMES USD 338.34M 72.51M Dec/2025
Alnylam Pharmaceuticals USD 829.31M 219.56M Dec/2025
Amarin USD 22.21M 28.15M Sep/2025
ANI Pharmaceuticals USD 124.18M 12.39M Dec/2025
Anika Therapeutics USD 14.68M 9.46M Mar/2025
Arrowhead Research USD 256.47M 228.7M Sep/2025
Eisai JPY 168.85B 17.02B Dec/2025
Esperion Therapeutics USD -29.52M 32.4M Sep/2024
GlaxoSmithKline GBP 6.18B 106M Dec/2025
Heron Therapeutics USD 23.35M 1.6M Sep/2024
Insmed USD 217.69M 106.25M Dec/2025
Ligand Pharmaceuticals USD 155.28M 82.42M Sep/2025
Merck USD 13.42B 431M Sep/2025
Nektar Therapeutics USD 13.75M 650K Jun/2024
Neurocrine Biosciences USD 787.9M 7M Dec/2025
Omeros USD -33.16M 18.52M Jun/2024
Pacira USD 142.25M 11.34M Dec/2025
Regeneron Pharmaceuticals USD 3.3B 67M Dec/2025
Roche Holding CHF 22.09B 10.04B Dec/2025
Sangamo BioSciences -2.39M 1.09M Jun/2024
Surmodics USD -11.54M 3.99M Sep/2024
Ultragenyx Pharmaceutical USD 178M 46.06M Dec/2025
Veracyte USD 101.97M 10.69M Dec/2025
Vertex Pharmaceuticals USD 2.72B 62.4M Dec/2025